Skip to main content

1-6 of 6 results for subject:Pfizer

Subject X
Business

Type

House

Session

Year

Department

Member

Primary member

Answering member

Legislative stage

Legislation

Subject

More
Business (6)

Publisher


Show detailed: On Off
Results: 10 20 50 100
Sort by: Newest first Oldest first

Will the Leader of the House find time for a debate on the Department of Health's drugs procurement process in relation to companies such as Pfizer, to ensure that corporate social responsibility comes into the process?

Member
Laura Sandys (Conservative)
Type
Business questions
Date
24 March 2011
Reference
525 c1101
House
House of Commons

I applaud my hon. Friend's campaign on behalf of those in her constituency who are threatened by the decision taken by Pfizer. I will certainly draw the attention of my right hon. Friend the Secretary of State for Health to her request for more corporate social responsibility. It might also...

Member
Lord Young of Cookham (Conservative)
Type
Proceeding contributions
Date
24 March 2011
Reference
525 c1101
House
House of Commons
Answered by
Baroness Beckett (Labour)
Answering body
Department of Trade and Industry
Type
Oral answers to questions
Date
14 May 1998
Reference
312 c511-2;312 c513-4
House
House of Commons
1st supplementary on effect of staff investment on competitiveness and success of Pfizer.
Asked by
Stephen Ladyman (Labour)
Answering body
Department of Trade and Industry
Oral questions - 1st Supplementary
Status
Answered
Date
14 May 1998
Reference
312 c511-2;312 c513-4
House
House of Commons
To comment on the progress of her Competitiveness UK initiative. -
Asked by
Stephen Ladyman (Labour)
Answering body
Department of Trade and Industry
Oral questions - Lead
Status
Answered
Date
14 May 1998
Reference
312 c511-2;312 c513-4; 40966
House
House of Commons
Answered by
Baroness Beckett (Labour)
Answering body
Department of Trade and Industry
Type
Oral answers to questions
Date
14 May 1998
Reference
312 c511-2;312 c513-4
House
House of Commons